Nancy Klein
Seattle, WANPI 1255424131
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $40,767 of the $46,032 with a category attached, or 88.6%. Ferring Pharmaceuticals Inc. accounts for 83.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $32,538 and has fallen 99.9% since, to $38 in 2025.
Across 61 payments — averaging $754.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$38K
- Merck$5K
- EMD Serono, Inc.$3K
- AbbVie$25
Across 43 payments — averaging $21,923 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ferring International Pharmascience Center US$943K
What the payments were for
- Consulting fees$40,76789%
- Grants$250%
- Travel & lodging$4,0709%
- Food & beverage$1,1703%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 47 | $38,490 |
| Merck | 9 | $4,728 |
| EMD Serono, Inc. | 4 | $2,789 |
| AbbVie | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.